scholarly journals HERV-K and HERV-H env Proteins Induce a Humoral Response in Prostate Cancer Patients

Pathogens ◽  
2022 ◽  
Vol 11 (1) ◽  
pp. 95
Author(s):  
Maria Antonietta Manca ◽  
Tatiana Solinas ◽  
Elena Rita Simula ◽  
Marta Noli ◽  
Stefano Ruberto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Humoral Response ◽  
Intraepithelial Neoplasia ◽  
Endogenous Retroviruses ◽  
Prostate Hyperplasia ◽  
Human Endogenous Retroviruses ◽  
Prostate Intraepithelial Neoplasia ◽  
Atypical Small Acinar Proliferation ◽  
New Evidence ◽  
Benign Prostate

A higher expression of human endogenous retroviruses (HERVs) has been associated with several malignancies, including prostate cancer, implying a possible use as a diagnostic or prognostic cancer biomarker. For this reason, we examined the humoral response against different epitopes obtained from the envelope protein of HERV-K (HERV-K env-su19–37, HERV-K env-su109–126), HERV-H (HERV-H env-su229–241, HERV-H env387–399) and HERV-W (HERV-W env-su93–108, HERV-W env-su248–262) in the plasma of patients affected by prostate cancer (PCa), and compared to that of benign prostate hyperplasia (BPH) and a borderline group of patients with atypical small acinar proliferation (ASAP) and prostate intraepithelial neoplasia (PIN) and healthy controls. A significant antibody response was observed against HERV-K env-su109–126 (p = 0.004) and HERV-H env-su229–241 (p < 0.0001) in PCa patients compared to HCs, BPH and borderline cohorts, whilst no significance difference was found in the antibodies against HERV-W env-su93–108 and HERV-W env-su248–262 in patients with PCa. Our results provided further proof of the association between HERV-K and PCa and added new evidence about the possible involvement of HERV-H in PCa pathogenesis, highlighting their possibility of being used as biomarkers of the disease.

Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia

2020 ◽  
Vol 51 (6) ◽  
pp. 566-573 ◽  
Author(s):  
Pavel A Markin ◽  
Alex Brito ◽  
Natalia Moskaleva ◽  
Miguel Fodor ◽  
Ekaterina V Lartsova ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Mass Spectrometry ◽  
Gas Chromatography ◽  
Diagnostic Accuracy ◽  
Benign Prostate Hyperplasia ◽  
Intraepithelial Neoplasia ◽  
Prostatic Intraepithelial Neoplasia ◽  
Gas Chromatography Mass Spectrometry ◽  
Prostate Hyperplasia ◽  
Benign Prostate

Abstract Objective Sarcosine was postulated in 2009 as a biomarker for prostate cancer (PCa). Here, we assess plasma sarcosine as a biomarker that is complementary to prostate-specific antigen (PSA). Methods Plasma sarcosine was measured using gas chromatography-mass spectrometry (GC-MS) in adults classified as noncancerous controls (with benign prostate hyperplasia [BPH], n = 36), with prostatic intraepithelial neoplasia (PIN, n = 16), or with PCa (n = 27). Diagnostic accuracy was assessed using receiver operating characteristic curve analysis. Results Plasma sarcosine levels were higher in the PCa (2.0 µM [1.3–3.3 µM], P &lt;.01) and the PIN (1.9 µM [1.2–6.5 µM], P &lt;.001) groups than in the BPH (0.9 µM [0.6–1.4 µM]) group. Plasma sarcosine had “good” and “very good” discriminative capability to detect PIN (area under the curve [AUC], 0.734) and PCa (AUC, 0.833) versus BPH, respectively. The use of PSA and sarcosine together improved the overall diagnostic accuracy to detect PIN and PCa versus BPH. Conclusion Plasma sarcosine measured by GC-MS had “good” and “very good” classification performance for distinguishing PIN and PCa, respectively, relative to noncancerous patients diagnosed with BPH.

scholarly journals Prostate Stem Cells in the Development of Benign Prostate Hyperplasia and Prostate Cancer: Emerging Role and Concepts

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Akhilesh Prajapati ◽  
Sharad Gupta ◽  
Bhavesh Mistry ◽  
Sarita Gupta
Keyword(s):  
Prostate Cancer ◽  
Stem Cells ◽  
Benign Prostate Hyperplasia ◽  
Normal Prostate ◽  
Prostate Hyperplasia ◽  
Regulatory Factors ◽  
Prostate Cells ◽  
Hormonal Imbalance ◽  
Benign Prostate ◽  
Insight Into

Benign Prostate hyperplasia (BPH) and prostate cancer (PCa) are the most common prostatic disorders affecting elderly men. Multiple factors including hormonal imbalance, disruption of cell proliferation, apoptosis, chronic inflammation, and aging are thought to be responsible for the pathophysiology of these diseases. Both BPH and PCa are considered to be arisen from aberrant proliferation of prostate stem cells. Recent studies on BPH and PCa have provided significant evidence for the origin of these diseases from stem cells that share characteristics with normal prostate stem cells. Aberrant changes in prostate stem cell regulatory factors may contribute to the development of BPH or PCa. Understanding these regulatory factors may provide insight into the mechanisms that convert quiescent adult prostate cells into proliferating compartments and lead to BPH or carcinoma. Ultimately, the knowledge of the unique prostate stem or stem-like cells in the pathogenesis and development of hyperplasia will facilitate the development of new therapeutic targets for BPH and PCa. In this review, we address recent progress towards understanding the putative role and complexities of stem cells in the development of BPH and PCa.

scholarly journals Overexpression of MiR-155-5p and increased number of macrophage population in precancerous prostatic disease

2020 ◽  
Vol 11 (2) ◽  
pp. 85-91
Author(s):  
Rachma Greta Putri ◽  
Sari Eka Pratiwi ◽  
Didik Setyo Heriyanto ◽  
Danarto Danarto ◽  
Indwiani Astuti ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Reverse Transcriptase ◽  
Benign Prostate Hyperplasia ◽  
Intraepithelial Neoplasia ◽  
Prostate Adenocarcinoma ◽  
Prostatic Intraepithelial Neoplasia ◽  
High Grade ◽  
Prostate Hyperplasia ◽  
Macrophage Population ◽  
Benign Prostate

Latar Belakang: Gangguan regulasi mikroRNA(miR) dan inflamasi kronik dapat mengubah tumor menjadi karsinoma dan kanker dengan metastasis melalui perubahan seluler dan genomik. Lesi prekanker memiliki peluang 33,3 persen menjadi kanker. Penelitian ini bertujuan untuk mengkaji peran miR-155-5p terhadap mRNA SOCS1 dan populasi makrofag terhadap progresivitas penyakit yang berhubungan dengan Benign Prostate Hyperplasia (BPH), High Grade Prostatic Intraepithelial Neoplasia (HGPIN), dan Prostate Adenocarcinoma (PRAD). Metode: Penelitian ini merupakan penelitian potong lintang dengan 3 kelompok, yaitu BPH,HGPIN, dan PRAD. Sampel jaringan didapatkan dari Tindakan TURP. Ekspresi miR-155 dianalisis menggunakan qPCR dan dikalkulasi menggunakan metode Livak. Ekspresi mRNA SOCS-1 dianalisis menggunakan reverse transcriptase PCR. Penanda pan makrofag, anti CD-68 monoclonal antibody(MoAb) digunakan untuk mendeteksi populasi makrofag pada jaringan dengan imunohistokimia. Hasil: Ekspresi miR-155 lebih tinggi pada HGPIN dibandingkan BPH dan PRAD (p=0,14). Ekspresi mRNA SOCS1 pada HGPIN paling rendah diantara ketiga sampel (p=0,96). Terdapat korelasi negative antara miR-155 dan mRNA SOCS1 (p=0,02). Terdapat peningkatan persentase populasi makrofag yang signifikan pada HGPIN (6,03 persen) dibandingkan BPH (0.89 persen) dengan p=0,00. Kesimpulan: Pada penelitian ini, terdapat perubahan persentase makrofag dan miR-155 pada HGPIN. Variasi ekspresi miR-155 dan persentase populasi makrofag dapat disebabkan karena perubahan epigenetik. Oleh sebab itu, perlu penelitian lebih lanjut untuk memvalidasi hasil tersebut dan memahami  kemungkinan menjadi biomarker pada penyakit prekanker pada prostat. Kata Kunci: Prostatic Intaepithelial Neoplasia, miR-155, Makrofag   Abstract   Background: Impaired microRNA(miR) regulation and chronic inflammation could transform tumors into carcinoma and cancer by metastasis through cellular and genomic changes. Precancerous lesions have a 33.3 percent chance of becoming cancerous. This study investigated the role of miR-155 related to SOCS1 mRNA and macrophage population in disease progression associated  with Benign Prostate Hyperplasia (BPH), High-Grade Prostatic Intraepithelial Neoplasia (HGPIN), and Prostate Adenocarcinoma (PRAD). Methods: This was a cross-sectional study using three groups of samples, namely BPH, HGPIN, and PRAD. Tissue samples were obtained from TURP Action. The expression of miR-155 was analyzed using real-time qPCR and calculated using the Livak method. The expression of SOCS1 mRNA was analyzed using reverse transcriptase PCR. The macrophage pan-marker, anti-CD68 monoclonal antibody (MoAb), was used to detect macrophage population in tissues by immunohistochemistry. Results: The expression of miR-155 was higher in HGPIN than BPH and PRAD (p=0.14). The expression of SOCS1 mRNA in HGPIN was the lowest among the three samples (p=0.96). There was a negative correlation between miR-155 and SOCS1 mRNA (p=0.02). There was a significant increase in the percentage of the macrophage population in HGPIN (6.03 percent) compared to BPH (0.89 percent) with p=0.00. Conclusion: In this study, there were changes in the percentage of macrophage and miR-155 in HGPIN. The variation in miR-155 expression and the percentage of the macrophage may be caused by epigenetic changes. Therefore, further research is needed to validate these results and understand the possibility of being a biomarker in precancerous disease of the prostate. Keywords: Prostatic Intraepithelial Neoplasia, miR-155, Macrophage  

scholarly journals The Association between Trichomonas Vaginalis Infection and The Risk of Benign Prostate Hyperplasia, Prostate Cancer, and Bladder Cancer in Patients: A Nationwide Population-Based Case-Control Study

2021 ◽  
Author(s):  
Hung Yi Yang ◽  
Ruei-Yu Su ◽  
Chi-Hsiang Chung ◽  
Kuo-Yang Huang ◽  
Wu-Chien Chien ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bladder Cancer ◽  
Trichomonas Vaginalis ◽  
Case Control Study ◽  
Benign Prostate Hyperplasia ◽  
Case Control ◽  
Control Group ◽  
Prostate Hyperplasia ◽  
Benign Prostate ◽  
Control Study

Abstract Introduction: Trichomonas vaginalis infection is one of the most widespread sexually transmitted infections in the world. There are approximately 276 million cases worldwide. Most men remain undiagnosed and untreated because they are asymptomatic. The chronic inflammation induced by persistent infection may increase the risk of developing genitourinary cancers. In this study, we aimed to investigate the association between trichomoniasis and benign prostate hyperplasia (BPH), prostate cancer (PCa), and bladder cancer (BC) in Taiwan.Material and method: We designed a case-control study by using the database of the National Health Insurance program in Taiwan. We used the International Classification of Diseases, 9th Revision classifications to classify all the medical conditions in the case and control groups. All odds ratios (ORs) and 95% confidence intervals (CIs) were analyzed using multivariable logistic regression to adjust for all comorbidities and variables.Result: From 2000 to 2015, we enrolled a total of 62,544 individuals as the case group and 187,632 as the control group. Trichomoniasis exposure had a significant association with BPH and PCa (adjusted OR: BPH = 2.685, 95% CI = 1.233–4.286, P = 0.013; PCa = 5.801, 95% CI = 1.296–26.035, P = 0.016). The relative risk was much higher if patients had both trichomoniasis and depression (adjusted OR = 7.682, 95% CI = 5.730–9.451, P < 0.001).Conclusion: Men with trichomoniasis had a significantly higher risk of developing BPH and PCa than those without. Healthcare professionals should not only pay more attention to disease treatment, but also to public health education.

scholarly journals Identification of hub genes and their clinical value for predicting the development of prostate cancer from benign prostate hyperplasia by bioinformatic analysis

2021 ◽  
Author(s):  
Xi Chen ◽  
Junjie Ma ◽  
Chengdang Xu ◽  
Licheng Wang ◽  
Yicong Yao ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Survival Data ◽  
Benign Prostate Hyperplasia ◽  
Disease Free Survival ◽  
Ppi Network ◽  
Hub Genes ◽  
Prostate Hyperplasia ◽  
Hub Gene ◽  
Benign Prostate ◽  
Geo Database

Abstract BackgroundProstate cancer (PCa) and benign prostate hyperplasia (BPH) are commonly encountered diseases in elderly males. The two diseases have some commonalities: both are growth depend on hormone and respond to antiandrogen therapy. Some studies have shown that genetic factors are responsible for the occurrences of both diseases. There may be a correlation between BPH and PCa. MethodsThe GEO database can help determine the differentially expressed genes (DEGs) between BPH and PCa. Gene Ontology (GO) term enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were utilized to find pathways in which the DEGs were enriched. The STRING database can provide a protein–protein interaction (PPI) network, and Cytoscape software can find hub genes in PPI network. GEPIA can be used to analyze expression and survival data for hub genes. R software was used to progress regression analysis, decision curve analysis and built nomograph. UALCAN and The Human Protein Atlas was utilized to test the results. Finally, we made clinical and cell experiments to verify the results.ResultsSixty DEGs, consisting of 15 up-regulated and 45 down-regulated genes, were found based on the GEO database. Using Cytoscape, we found 7 hub gene in the PPI network. The hub gene expression was tested on TCGA database. Except CXCR4, all hub genes expressed differently between tumor and normal samples. Meanwhile, all hub genes exclude CXCR4 has diagnostic value in predicting PCa and their mutations are risk factors leading to PCa. The expression of CSRP1, MYL9 and SNAI2 changed in different tumor stage. CSRP1 and MYH11 could affect the disease-free survival (DFS). The same results reflected in different database. In addition, we also chose three hub gene, MYC, MYL9, and SNAI2, to validate their functions in clinical specimens and cells.ConclusionThese identified hub genes can help us to understand the process and mechanism by which BPH develops into PCa and provide achievable targets for predicting which BPH patients may later develop PCa.

scholarly journals Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Chun-Jen Hsiao ◽  
Tzong-Shin Tzai ◽  
Chein-Hung Chen ◽  
Wen-Horng Yang ◽  
Chung-Hsuan Chen
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Clinical Sample ◽  
Specific Antigen ◽  
Ion Accumulation ◽  
Detection Sensitivity ◽  
Prostate Hyperplasia ◽  
Liquid Chromatography Tandem Mass ◽  
Benign Prostate

Glycans of prostate-specific antigen (PSA) in prostate cancer were found to be different from that in benign disease. It is difficult to analyze heterogeneous PSA glycoforms in each individual specimen because of low protein abundance and the limitation of detection sensitivity. We developed a method for prostate cancer diagnosis based on PSA glycoforms. Specific glycoforms were screened in each clinical sample based on liquid chromatography-tandem mass spectrometry with ion accumulation. To look for potential biomarkers, normalized abundance of each glycoform in benign prostate hyperplasia (BPH) and in prostate cancer was evaluated. The PSA glycoform, Hex5HexNAc4NeuAc1dHex1, and monosialylated, sialylated, and unfucosylated glycoforms differed significantly between the prostate cancer and BPH samples. The detection sensitivity (87.5%) and specificity (60%) for prostate cancer identification are higher than those of the serum PSA marker. As low as 100 amol PSA could be detected with the ion accumulation method which has not been reported before. The improved detection specificity can help reduce unnecessary examinations.

scholarly journals The Panel of 12 Cell-Free MicroRNAs as Potential Biomarkers in Prostate Neoplasms

Diagnostics ◽  
2020 ◽  
Vol 10 (1) ◽  
pp. 38 ◽  
Author(s):  
Maria Yu. Konoshenko ◽  
Evgeniy A. Lekchnov ◽  
Olga E. Bryzgunova ◽  
Ivan A. Zaporozhchenko ◽  
Sergey V. Yarmoschuk ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Large Scale ◽  
Benign Prostate Hyperplasia ◽  
Scale Validation ◽  
Biological Fluids ◽  
Prostate Neoplasms ◽  
Great Promise ◽  
Prostate Hyperplasia ◽  
Diagnostic Potential ◽  
Benign Prostate

Prostate cancer is a global biological, medical, and social issue aggravated by the lack of reliable, highly specific, and sensitive non-invasive tests for diagnosis and staging of prostate cancer. One prospective source of biomarkers are the cell-free miRNAs present in various biological fluids. In the present study, we validated the diagnostic potential of cell-free miRNAs: miR-19b, miR-22, miR-92a, miR-378, miR-425, miR-30e, miR-31, miR-125b, miR-200b, miR-205, miR-375, and miR-660; we estimated the required sample size and the minimal miRNA set for a subsequent large-scale validation study. Relative expression of 12 miRNA combined in 31 ratios was investigated in three fractions of biological fluids (urine extracellular vesicles, clarified urine, and plasma) obtained from patients with prostate cancer (n = 10), benign prostate hyperplasia (n = 8), and healthy volunteers (n = 11). Eight of the miRNAs found in urine vesicles (miR-19b, miR-30e, miR-31, miR-92a, miR-125, miR-200, miR-205, and miR-660) showed great promise and when combined into six ratios (miR-125b/miR-30e, miR-200/miR-30e, miR-205/miR-30e, miR-31/miR-30e, miR-660/miR-30e, and miR-19b/miR-92a) could classify patients with prostate cancer, benign prostate hyperplasia, and healthy donors with 100% specificity, 100% sensitivity, and with a high degree of reliability for most donors.

Sign in / Sign up

Export Citation Format

Share Document